Unknown

Dataset Information

0

Case Report: Anlotinib Therapy in a Patient With Recurrent and Metastatic RAIR-DTC Harboring Coexistent TERT Promoter and BRAFV600E Mutations.

ABSTRACT: We describe a case of recurrent and metastatic radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC) treated with anlotinib in this report. The patient was randomized to placebo initially, after disease progressed at C8 (C is the treatment cycle), the patient was referred to the open label therapy of anlotinib, 12 mg p.o. daily with a 2-week on/1-week off regimen. Partial response was achieved at C2 with anlotinib treatment. To date, over 37 months of progression-free survival (PFS) has been achieved. Adverse effects were tolerable and manageable in this patient. Molecular characterization revealed coexistent C228T mutation of TERT promoter and BRAFV600E mutations. Favorable clinical outcome in this patient suggests that anlotinib might provide a novel effective therapeutic option for patients with RAIR-DTC. TERT and BRAFV600E mutations may represent as biomarker for predicting salutary effects of anlotinib.

SUBMITTER: Su Y 

PROVIDER: S-EPMC8024690 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Case Report: Anlotinib Therapy in a Patient With Recurrent and Metastatic RAIR-DTC Harboring Coexistent TERT Promoter and BRAF<sup>V600E</sup> Mutations.

Su Yanjun Y   Cheng Shaohao S   Qian Jun J   Zhang Min M   Li Tuanli T   Zhang Ying Y   Diao Chang C   Zhang Ling L   Cheng Ruochuan R  

Frontiers in oncology 20210324

We describe a case of recurrent and metastatic radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC) treated with anlotinib in this report. The patient was randomized to placebo initially, after disease progressed at C8 (C is the treatment cycle), the patient was referred to the open label therapy of anlotinib, 12 mg p.o. daily with a 2-week on/1-week off regimen. Partial response was achieved at C2 with anlotinib treatment. To date, over 37 months of progression-free survival (  ...[more]

Similar Datasets

Unknown Neoadjuvant therapy with anlotinib in a locally advanced and pulmonary metastasis PTC patient harboring TERT promoter and BRAF<sup>V600E</sup> mutations: a case report.
| S-EPMC10660997 | biostudies-literature
Unknown TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAF<sup>V600E</sup>/TERT promoter double-mutated glioma.
| S-EPMC6685154 | biostudies-literature
Unknown Synergistic activation of mutant TERT promoter by Sp1 and GABPA in BRAF<sup>V600E</sup>-driven human cancers.
| S-EPMC7822828 | biostudies-literature
Unknown Anticancer effects of combinational treatment with BRAF<sup>V600E</sup> siRNA and PI3K pathway inhibitors in melanoma cell lines harboring BRAF<sup>V600E</sup>.
| S-EPMC6006476 | biostudies-literature
Unknown BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Carcinoma in Chinese Patients.
| S-EPMC4827831 | biostudies-literature
Unknown Combined BRAF<sup>V600E</sup> and MEK blockade for BRAF<sup>V600E</sup>-mutant gliomas.
| S-EPMC5560871 | biostudies-literature
Unknown Papillary thyroid cancer organoids harboring BRAF<sup>V600E</sup> mutation reveal potentially beneficial effects of BRAF inhibitor-based combination therapies.
| S-EPMC9827684 | biostudies-literature
Unknown BRAF<sup>non-V600E</sup> more frequently co-occurs with IDH1/2 mutations in adult patients with gliomas than in patients harboring BRAF<sup>V600E</sup> but without a survival advantage.
| S-EPMC8114535 | biostudies-literature
Unknown TERT Promoter and BRAF V600E Mutations in Papillary Thyroid Cancer: A Single-Institution Experience in Korea.
| S-EPMC9563418 | biostudies-literature
Unknown Telomere dysfunction in Tert knockout mice delays Braf&lt;sup&gt;V600E&lt;/sup&gt; -induced melanoma development.
| S-EPMC10840707 | biostudies-literature